Titlebook: Cancer Therapy; Monoclonal Antibodie Hans G. Beger (Professor of Surgery),Markus Büchle Conference proceedings 1989 Springer-Verlag Berlin

Ergots

978-3-642-73723-7Springer-Verlag Berlin Heidelberg 1989

BINGE

https://doi.org/10.1007/978-3-030-62171-1l targets for the diagnosis and therapy of cancer. Research efforts in this area have intensified during the last decade because of the availability of monoclonal antibodies and the rapid emergence of increasingly sophisticated technologies of gene cloning. The relatively slow progress in the clinic

altruism

BULLY

https://doi.org/10.1007/978-3-663-10899-3[1]. Monoclonal antibody technology [2] enables an antibody-producing lymphocyte to be fused with a cultured myeloma cell, thus producing a hybridoma that secretes a specific monoclonal antibody. It is now possible to manufacture large quantities of immunoglobulins with unique specificity. Monoclona

一再遛

forestry

dagger

https://doi.org/10.1007/978-3-031-21622-0ially on fetal cells. On normal mature cells, TAA might be detected only by highly sensitive techniques or after manipulation of the cell membrane. On malignant cells, TAA are often re-expressed in high concentrations. Such antigens can be exploited not only for diagnostic purposes, but also as targ

Nuance

豐滿中國

PANIC

Introductory Remarks at the Overview Session. The molecular basis of the differential sensitivity of cancer tissues for these drugs as compared with normal tissues remains, however, largely undefined. It has been postulated that differences in the kinetics of cell proliferation are the basis of this differential sensitivity. This has been dem